Your logo

Prostate News Archive


  • Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refractory Prostate Cancer (Medical News Today)

    Ascenta Therapeutics announced positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P) in men with docetaxel refractory, castrate resistant prostate cancer (CRPC) at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, FL.

  • FDA calls Glaxo ad for prostate drug 'misleading' (San Francisco Chronicle)

    A marketing campaign for a GlaxoSmithKline prostate drug has drawn complaints from federal regulators, who said the space-themed advertisement is misleading. The British drugmaker's Avodart capsules treat symptoms of enlarged prostate, including frequent...

  • FDA Says Glaxo Prostate Drug Ad Misleads (

    The FDA says an ad for Glaxo's prostate drug Avodart makes false statements

  • UIC receives $3 million to study prostate cancer risk factors (EurekAlert!)

    ( University of Illinois at Chicago ) Researchers at the University of Illinois at Chicago's Institute for Health Research and Policy have been awarded a five-year, $3 million grant from the National Cancer Institute to study the link between body fat and prostate cancer progression.

  • Back to Prostate News Archive